Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text

Life Sciences, Hematology, Oncology +16

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter et al. · New England Journal of Medicine · 2008 · 1.6K citations

Life Sciences, Genetics, Molecular Genetics +17

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

Marta Pratcorona, Salut Brunet, Josep Nomdedéu et al. · Blood · 2013 · 282 citations

Medicine, Hematology, Oncology +12

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC)

Miriam Miesner, Claudia Haferlach, Ulrike Bacher et al. · Blood · 2010 · 125 citations · Full text

Medicine, Hematology, Oncology +17

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)

Brunangelo Falini, Katja Macijewski, Tamara Weiss et al. · Blood · 2010 · 121 citations · Full text

Medicine, Oncology, Pathology +5